Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 15, 2019
Event: Announcement of the pricing of its best efforts initial public offering (IPO).
Status: Emerging Growth Company.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes
The material change reported is the pricing of the Company's initial public offering. No comparative financial period data is included in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) announcing the IPO pricing. Specific details regarding the offering size, share price, or proceeds are contained in the attached press release and are not explicitly detailed in the body of this 8-K summary text.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this filing beyond the standard disclosure of the IPO event.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific IPO pricing, share count, and total proceeds.
- Verify the final prospectus for underwriting terms and use of proceeds.
- Confirm the ticker symbol and listing exchange following the IPO pricing.
- Check subsequent filings (e.g., S-1/A or 424(b)) for updated financial data and risk factors.